| Today's Big NewsOct 28, 2022 |
|
A GPS to your next blockbuster drug - Design molecules towards your desired properties through AI+Biophysics. Learn more. 
|
|
| By Kevin Dunleavy Nearly two years after shelling out $1.4 billion for MYR and its hepatitis D drug , Gilead has yet to gain sanction for bulevirtide in the U.S., and it’s not happening any time soon as the FDA has given it a thumbs down. |
|
|
|
By Nick Paul Taylor The dream of taming IL-2 keeps slipping further away. After seeing Bristol Myers Squibb and Nektar Therapeutics give up on their candidate, Sanofi has reported “lower than projected” efficacy data on its prospect and rethought its plans for the molecule. |
By Conor Hale On the backs of a waning COVID-19 pandemic and global supply chain disruptions, the FDA expects that a broader slowdown in the pace of medtech innovation will result in a dip in the number of new devices approved by the agency this year. |
By Robert King MACPAC is calling on states and CMS to publicly release key progress reports on the unwinding of the COVID-19 emergency, which will spark a massive redetermination of Medicaid eligibility. |
By Zoey Becker Last quarter, Gilead Sciences said it was aiming to ramp up its oncology franchise. That goal played out nicely for the company in its latest earnings report, with third-quarter sales skyrocketing 79% year over year. Gilead aims to derive a third of its revenue from oncology products by 2030, the company announced in April. |
By Max Bayer A new STAT News investigation has found that Eisai's experimental Alzheimer's drug lecenemab may have contributed to a patient's death, according to documents obtained by the outlet. The Japanese pharma acknowledged the death but wouldn't divulge specific details citing patient privacy. |
By Fraiser Kansteiner Women worldwide who count on Ferring Pharmaceuticals' flagship fertility drug may be out of luck for the foreseeable future. Ferring Pharmaceuticals has paused global shipments of the injectable med, citing changes in the manufacturing process by its third-party supplier. |
By Dave Muoio A new review of COVID-era telehealth use highlights potential quality shortcomings resulting from virtual care. Researchers say its vital information as providers and policymakers weigh telehealth's role in post-pandemic care. |
By Kevin Dunleavy Five weeks after getting a harsh thumbs down from the FDA for its multiple myeloma treatment, Pepaxto, Oncopeptides has delivered something of a parting shot—phase 3 results that show what the company calls in its press release a “clinical benefit” for the drug. The agency halted confirmatory trials and pulled the drug off the market after negative results from one of those studies. |
By Nick Paul Taylor Vultures are circling Quantum Genomics. A high-stakes phase 3 hypertension readout has gone against the French biotech, prompting it to stop work on firibastat in cardiology and reallocate its remaining 11 million euros ($11 million) to other projects. |
By Andrea Park During a call with investors on Thursday, CEO Mick Farrell reported that snags in the supply chain are beginning to smooth out, putting ResMed on track to ramp up production in the coming months. |
By Andrea Park Months after its G7 continuous glucose monitor landed European approval in March—leading to a wide-scale rollout of the sensor across the continent earlier this month—Dexcom is zeroing in on the U.S. market. |
By Anastassia Gliadkovskaya Launched in 2016, the company develops clinically designed VR lessons that help teach life skills aimed at children with autism and other neurodevelopmental disorders. |
By Gabrielle Masson An increasingly bitter conflict between biotech and investor has come to a close, with Mereo BioPharma losing out to Rubric Capital Management and handing the activist investor four spots on its board. |
By Sharon Klahr Coey Roche’s Genentech’s Diversity and Inclusion team is not afraid to ask the hard questions when it comes to the hurdles Black women face dealing with healthcare. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
